Iska Moxon-Emre1, Eric Bouffet1, Michael D Taylor1, Normand Laperriere1, Nadia Scantlebury1, Nicole Law1, Brenda J Spiegler1, David Malkin1, Laura Janzen1, Donald Mabbott2. 1. Iska Moxon-Emre, Eric Bouffet, Michael D. Taylor, Nadia Scantlebury, Nicole Law, Brenda J. Spiegler, David Malkin, Laura Janzen, and Donald Mabbott, Hospital for Sick Children; Iska Moxon-Emre, Michael D. Taylor, Normand Laperriere, Brenda J. Spiegler, David Malkin, and Laura Janzen, University of Toronto; and Normand Laperriere, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario, Canada. 2. Iska Moxon-Emre, Eric Bouffet, Michael D. Taylor, Nadia Scantlebury, Nicole Law, Brenda J. Spiegler, David Malkin, Laura Janzen, and Donald Mabbott, Hospital for Sick Children; Iska Moxon-Emre, Michael D. Taylor, Normand Laperriere, Brenda J. Spiegler, David Malkin, and Laura Janzen, University of Toronto; and Normand Laperriere, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario, Canada. donald.mabbott@sickkids.ca.
Abstract
PURPOSE: To examine the impact of radiation (ie, craniospinal irradiation [CSR] dose and boost volume) and complications (ie, hydrocephalus and other neurologic complications, including mutism) on patterns of change in intellectual functioning in medulloblastoma survivors. PATIENTS AND METHODS: We conducted a retrospective review of 113 patients treated for medulloblastoma between 1983 and 2011 who were seen for neuropsychological assessment, including longitudinal follow-up of intellectual function. Patients were treated with either standard-dose CSR with a posterior fossa (PF) boost (n=51), standard-dose CSR plus tumor bed (TB) boost (n=9), reduced-dose CSR plus PF boost (n=28), or reduced-dose CSR plus TB boost (n=23), with or without chemotherapy. A subset of patients developed hydrocephalus that required cerebrospinal fluid (CSF) diversion (n=54) and/or other neurologic complications (n=40), more than half of which were postoperative mutism (n=25). Growth curve analysis was used to determine stability or change in intelligence scores over time. RESULTS: Patients treated with reduced-dose CSR plus TB boost showed stable intellectual trajectories, whereas patients treated with higher doses and larger boost volumes experienced intellectual declines. Presence of complications was associated with worse intellectual outcome; however, hydrocephalus requiring CSF diversion and mutism differed in their pattern of decline. CONCLUSION: These results improve our understanding of factors that impair intellectual outcome in patients treated for medulloblastoma. Lower doses of CSR and smaller boost volumes seem to mitigate intellectual decline. Our findings validate the use of TB boost and suggest PF boost should be reconsidered.
PURPOSE: To examine the impact of radiation (ie, craniospinal irradiation [CSR] dose and boost volume) and complications (ie, hydrocephalus and other neurologic complications, including mutism) on patterns of change in intellectual functioning in medulloblastoma survivors. PATIENTS AND METHODS: We conducted a retrospective review of 113 patients treated for medulloblastoma between 1983 and 2011 who were seen for neuropsychological assessment, including longitudinal follow-up of intellectual function. Patients were treated with either standard-dose CSR with a posterior fossa (PF) boost (n=51), standard-dose CSR plus tumor bed (TB) boost (n=9), reduced-dose CSR plus PF boost (n=28), or reduced-dose CSR plus TB boost (n=23), with or without chemotherapy. A subset of patients developed hydrocephalus that required cerebrospinal fluid (CSF) diversion (n=54) and/or other neurologic complications (n=40), more than half of which were postoperative mutism (n=25). Growth curve analysis was used to determine stability or change in intelligence scores over time. RESULTS:Patients treated with reduced-dose CSR plus TB boost showed stable intellectual trajectories, whereas patients treated with higher doses and larger boost volumes experienced intellectual declines. Presence of complications was associated with worse intellectual outcome; however, hydrocephalus requiring CSF diversion and mutism differed in their pattern of decline. CONCLUSION: These results improve our understanding of factors that impair intellectual outcome in patients treated for medulloblastoma. Lower doses of CSR and smaller boost volumes seem to mitigate intellectual decline. Our findings validate the use of TB boost and suggest PF boost should be reconsidered.
Authors: L Veneroni; L Boschetti; F Barretta; C A Clerici; F Simonetti; E Schiavello; V Biassoni; F Spreafico; L Gandola; E Pecori; B Diletto; G Poggi; F Gariboldi; R Sensi; M Massimino Journal: Childs Nerv Syst Date: 2017-08-02 Impact factor: 1.475
Authors: Ramy Ayoub; Rebecca M Ruddy; Elizabeth Cox; Adeoye Oyefiade; Daniel Derkach; Suzanne Laughlin; Benjamin Ades-Aron; Zahra Shirzadi; Els Fieremans; Bradley J MacIntosh; Cynthia B de Medeiros; Jovanka Skocic; Eric Bouffet; Freda D Miller; Cindi M Morshead; Donald J Mabbott Journal: Nat Med Date: 2020-07-27 Impact factor: 53.440
Authors: T de Rojas; M Puertas; F Bautista; I de Prada; M Á López-Pino; B Rivero; C Gonzalez-San Segundo; M Gonzalez-Vicent; A Lassaletta; L Madero; L Moreno Journal: Clin Transl Oncol Date: 2019-04-01 Impact factor: 3.405
Authors: Kimberly P Raghubar; Michael Lamba; Kim M Cecil; Keith Owen Yeates; E Mark Mahone; Christina Limke; David Grosshans; Travis J Beckwith; M Douglas Ris Journal: Pediatr Blood Cancer Date: 2018-06-01 Impact factor: 3.167
Authors: Bree R Eaton; Saveli Goldberg; Nancy J Tarbell; Miranda P Lawell; Sara L Gallotto; Elizabeth A Weyman; Karen A Kuhlthau; David H Ebb; Shannon M MacDonald; Torunn I Yock Journal: Neuro Oncol Date: 2020-09-29 Impact factor: 12.300